

**Pfizer Inc.** 275 North Field Drive Lake Forest, IL 60045

July 21, 2022

## Notification of Emergency Date Extension for Diltiazem Hydrochloride for Injection 100 mg Single Dose ADD-Vantage® Glass Vial

Dear Customer,

Pfizer has received approval from the U.S. Food and Drug Administration (FDA) of our emergency request to extend the use date of 15 lots of **Diltiazem Hydrochloride for Injection 100 mg Single Dose ADD-Vantage® Glass Vial**, NDC 00409-4350-03, to mitigate a shortage of this medically necessary product.

The lots listed in the table included at the end of this letter have been extended by twelve months past their labeled extended use date. The FDA is not requiring or recommending that the lots identified in the table be relabeled with new extended use dates. If replacement product becomes available during the extension period, customers are expected to replace and properly dispose of these affected lots as soon as possible. We anticipate that FDA's <u>website</u>, which lists extended use dates to assist with drug shortages, will also be updated to reflect this information.

If you have any questions, please call our Customer Service Department at 1-844-646-4398.

Thank you,

Ashley McHenry Portfolio Director, Anti-Infectives & ADD-Vantage Hospital U.S.



## Emergency Extended Use Dating for 15 Lots of Diltiazem Hydrochloride for Injection 100 mg Single Dose ADD-Vantage $^{\rm @}$ Glass Vial

Unit of Sale NDC	Unit of Use NDC	Product Description	Lot Number	Labeled Extended Use Date	New Extended Use Date
00409- 4350-03	00409- 4350-13	Diltiazem Hydrochloride for Injection 100 mg Single Dose ADD-Vantage <sup>®</sup> Glass Vial	16035DD 16090DD 16140DD 16145DD 16200DD	4/1/2022	4/1/2023
			17100DD 17150DD 17210DD 17350DD	5/1/2022	5/1/2023
			18075DD 18145DD 18330DD	6/1/2022	6/1/2023
			19060DD 19095DD 19135DD	7/1/2022	7/1/2023

